One of the most stubborn obstacles in cancer immunotherapy is not the tumor cell itself but the cellular entourage that surrounds it. In hepatocellular carcinoma, the most common form of primary liver cancer, immune checkpoint inhibitors have transformed outcomes for some patients, yet the majority either fail to respond or eventually relapse.
One of the most stubborn obstacles in cancer immunotherapy is not the tumor cell itself but the cellular entourage that surrounds it.
In hepatocellular carcinoma, the most common form of primary liver cancer, immune checkpoint inhibitors have transformed outcomes for some patients, yet the majority either fail to respond or eventually...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
One of the most stubborn obstacles in cancer immunotherapy is not the tumor cell itself but the cellular entourage that surrounds it. In hepatocellular carcinoma, the most common form of primary liver cancer, immune checkpoint inhibitors have transformed outcomes for some patients, yet the majority either fail to respond or eventually relapse.
Open the app view to save this story, compare related coverage, and continue from the same source.